This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kalmansohn, R. W. Articles by Kalmansohn, R. B. Search for Related Content PubMed PubMed Citation Articles by Kalmansohn, R. W. Articles by Kalmansohn, R. B. Pubmed/NCBI databases Medline Plus Health Information Statins Social Bookmarking                         What's this?

Present Status of HMG Reductase Inhibitors in Treatment of Dyslipidemia

David L. Schiff

Robert B. Kalmansohn, MD

852 S. Robertson Blvd. Los Angeles, CA 90035

HMG reductase inhibitors have significant desirable effects on patients with dyslipidemia. Multiple factors are involved in these desirable effects. Other factors that might play a role in the risk of coronary artery disease are fibrinogen concentration, homocysteine, Lp (a), small dense LDL, insulin resistance, and infection with chlamydia.

High-dose reductase inhibitors may be indicated in select patients. The ideal end point may be 150 mg/dL for adults.

Angiology, Vol. 49, No. 9, 801-805 (1998)
DOI: 10.1177/000331979804900903


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?